Issues related to importation of prescription drugs
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to coverage of vaccines in the Patient Protection and Affordable Care Act
issues related to FDA approval process for adjuvanted vaccines
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to patent reform
Duration: January 1, 2008
to
January 1, 2012
General Issues: Health Issues , Medicare/Medicaid , Copyright/Patent/Trademark , Budget/Appropriations
Spending: about $540,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate, Health & Human Services - Dept of (HHS),, U.S. Senate,, Health & Human Services - Dept of (HHS), White House Office, White House Office,
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2011
RICCHETTI INCORPORATED terminated an engagement in which they represented NOVARTIS on Jan. 18, 2012.
Original Filing: 300439995.xml
Lobbying Issues
Issues related to importation of prescription drugs
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to coverage of vaccines in the Patient Protection and Affordable Care Act
issues related to FDA approval process for adjuvanted vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2011
RICCHETTI INCORPORATED amended a lobbying report for representation of NOVARTIS in Q32011 on Oct. 18, 2011.
Original Filing: 300417675.xml
Lobbying Issues
issues related to flu preparedness and vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to noninterference in prescription drug pricing
issues related to settlement agreements with generic manufacturers
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to coverage of vaccines in the Patient Protection and Affordable Care Act
issues related to use of accelerated approval process for vaccines
issues related to FDA approval process for adjuvanted vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2011
RICCHETTI INCORPORATED amended a lobbying report for representation of NOVARTIS in Q22011 on July 19, 2011.
Original Filing: 300399412.xml
Lobbying Issues
issues related to flu preparedness and vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to noninterference in prescription drug pricing
issues related to settlement agreements with generic manufacturers
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to coverage of vaccines in the Patient Protection and Affordable Care Act
issues related to use of accelerated approval process for vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
In Q1, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on April 20, 2011.
Original Filing: 300377103.xml
Lobbying Issues
issues related to flu preparedness and vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to noninterference in prescription drug pricing
issues related to settlement agreements with generic manufacturers
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to coverage of vaccines in the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2011
RICCHETTI INCORPORATED amended a lobbying report for representation of NOVARTIS in Q12011 on April 20, 2011.
Original Filing: 300377128.xml
Lobbying Issues
issues related to flu preparedness and vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to noninterference in prescription drug pricing
issues related to settlement agreements with generic manufacturers
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
issues related to coverage of vaccines in the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2010
In Q4, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on Jan. 20, 2011.
Original Filing: 300354104.xml
Lobbying Issues
issues related to flu preparedness and vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to noninterference in prescription drug pricing
issues related to settlement agreements with generic manufacturers
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2010
In Q3, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on Oct. 20, 2010.
Original Filing: 300327878.xml
Lobbying Issues
issues related to flu preparedness and vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to noninterference in prescription drug pricing
issues related to settlement agreements with generic manufacturers
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2010
In Q2, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on July 20, 2010.
Original Filing: 300297380.xml
Lobbying Issues
issues related to pandemic flu preparedness funding and seasonal and H1N1 vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to drug safety legislation
issues related to noninterference in prescription drug pricing
issues related to the approval process for follow-on biologics
Issues related to settlement agreements with generic manufacturers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2010
In Q1, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on April 20, 2010.
Original Filing: 300275435.xml
Lobbying Issues
issues related to pandemic flu preparedness funding and seasonal and H1N1 vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to drug safety legislation
issues related to noninterference in prescription drug pricing
issues related to the approval process for follow-on biologics
Issues related to settlement agreements with generic manufacturers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2009
In Q4, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on Jan. 20, 2010.
Original Filing: 300246614.xml
Lobbying Issues
issues related to pandemic flu preparedness funding and seasonal and H1N1 vaccine availability
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to drug safety legislation
issues related to noninterference in prescription drug pricing
issues related to the approval process for follow-on biologics
Issues related to settlement agreements with generic manufacturers
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
issues affecting pharmaceutical manufacturers in HR 3590, the Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2009
In Q3, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on Oct. 16, 2009.
Original Filing: 300207034.xml
Lobbying Issues
issues related to pandemic flu preparedness funding
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to drug safety legislation
issues related to noninterference in prescription drug pricing
issues related to the approval process for follow-on biologics
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement and Medicaid rebates
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2009
In Q2, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on July 14, 2009.
Original Filing: 300176923.xml
Lobbying Issues
issues related to pandemic flu preparedness funding
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to drug safety legislation
issues related to noninterference in prescription drug pricing
issues related to the approval process for follow-on biologics
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2009
In Q1, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on April 20, 2009.
Original Filing: 300162003.xml
Lobbying Issues
issues related to pandemic flu preparedness funding
issues related to comparative effectiveness research
issued related to drug importation
issues related to direct to consumer advertisingissues related to drug safety legislation
issues related to noninterference in prescription drug pricing
issues related to the approval process for follow-on biologics
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to pharmaceutical reimbursement
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
issues related to patent reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2008
In Q4, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on Jan. 15, 2009.
Original Filing: 300119785.xml
Lobbying Issues
H.R. 4703, S. 2467, H.R. 4991 -- Vaccine Shortage Preparedness Act of 2008
S. 2467, H.R. 4703, H.R. 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
issues related to pandemic flu preparedness fundingS. 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S. 103 Combat Meth Act
H.R. 1908 and S. 1710 -- Patient Reform Act
H.R. 3162 -- Children's Health and Medicare Protection Act
S. 1505 -- Affordable Biologics for Consumers Act
S. 1695 -- Biolgoics Price Competition and Innovation Act
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2029 Physician Payments Sunshine Act
H.R. 6111 Tax Relief and Health Care Act
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization ActIssues related to pharmaceutical reimbursement in H.R. 6331 (Medicare Improvements for Patients and Providers Act)
H.R. 3023 -- Drug and Medical Device Company Gift Disclosure Act
H.R. 3963 -- Children Health Insurance Reauthorization Act
S. 2041 False Claims Act Correction Act
H.R. 3610 -- Food and Drug Import Safety Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1145 Patent Reform Act
H.R. 1908 Patent Reform Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2008
In Q3, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $30,000. The report was filed on Oct. 17, 2008.
Original Filing: 300096849.xml
Lobbying Issues
H.R. 4703, S. 2467, H.R. 4991 -- Vaccine Shortage Preparedness Act of 2008
S. 2467, H.R. 4703, H.R. 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
issues related to pandemic flu preparedness fundingS. 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S. 103 Combat Meth Act
H.R. 1908 and S. 1710 -- Patient Reform Act
H.R. 3162 -- Children's Health and Medicare Protection Act
S. 1505 -- Affordable Biologics for Consumers Act
S. 1695 -- Biolgoics Price Competition and Innovation Act
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
Issues related to funding for pandemic preparedness
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2029 Physician Payments Sunshine Act
H.R. 6111 Tax Relief and Health Care Act
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization ActIssues related to pharmaceutical reimbursement in H.R. 6331 (Medicare Improvements for Patients and Providers Act)
H.R. 3023 -- Drug and Medical Device Company Gift Disclosure Act
H.R. 3963 -- Children Health Insurance Reauthorization Act
S. 2041 False Claims Act Correction Act
H.R. 3610 -- Food and Drug Import Safety Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1145 Patent Reform Act
H.R. 1908 Patent Reform Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2008
In Q2, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $60,000. The report was filed on July 15, 2008.
Original Filing: 300065485.xml
Lobbying Issues
H.R. 4703, S. 2467, H.R. 4991 -- Vaccine Shortage Preparedness Act of 2008
S. 2467, H.R. 4703, H.R. 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
H.R. 970 and S. 1378 -- Dextromethorphan Distribution Act S. 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S. 103 Combat Meth Act
H.R. 1908 and S. 1710 -- Patient Reform Act
H.R. 3162 -- Children's Health and Medicare Protection Act
S. 1505 -- Affordable Biologics for Consumers Act
S. 1695 -- Biolgoics Price Competition and Innovation Act
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 2029 Physician Payments Sunshine Act
H.R. 6111 Tax Relief and Health Care Act
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization ActIssues related to pharmaceutical reimbursement in H.R. 6331 (Medicare Improvements for Patients and Providers Act)
H.R. 3023 -- Drug and Medical Device Company Gift Disclosure Act
H.R. 3963 -- Children Health Insurance Reauthorization Act
S. 2041 False Claims Act Correction Act
H.R. 3610 -- Food and Drug Import Safety Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1145 Patent Reform Act
H.R. 1908 Patent Reform Act
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2008
In Q1, RICCHETTI INCORPORATED lobbied for NOVARTIS , earning $60,000. The report was filed on April 17, 2008.
Original Filing: 300041015.xml
Lobbying Issues
H.R. 4703, S. 2467, HR 4991 -- Vaccine Shortage Preparedness Act of 2008
S 2467, HR 4703, HR 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
HR 970 and S 1378 -- Dextromethorphan Distribution Act of 2007S 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S 103 Combat Meth Act of 2005
HR 1908 -- and S 1710 -- Patent Reform Act of 2007
HR 3162 -- Children's Health and Medicare Protection Act of 2007
S 1505 -- Affordable Biologics for Consumers Act
S 1695 Biologics Price Competition and Innovation Act of 2007
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 2029 Physician Payments Sunshine Act of 2007
HR 6111 Tax Relief and Health Care Act (Medicare)
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization ActHR 3023 Drug and Medical Device Company Gift Disclosure Act
HR 3963 Children Health Insurance Reauthorization Act of 2007
S 2041 False Claims Act Correction Act of 2007
HR 3610 Food and Drug Import Safety Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 1145 Patent Reform Act of 2007
HR 1908 Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2008
RICCHETTI INCORPORATED amended a lobbying report for representation of NOVARTIS in Q12008 on April 17, 2008.
Original Filing: 300041135.xml
Lobbying Issues
H.R. 4703, S. 2467, HR 4991 -- Vaccine Shortage Preparedness Act of 2008
S 2467, HR 4703, HR 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
HR 970 and S 1378 -- Dextromethorphan Distribution Act of 2007S 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S 103 Combat Meth Act of 2005
HR 1908 -- and S 1710 -- Patent Reform Act of 2007
HR 3162 -- Children's Health and Medicare Protection Act of 2007
S 1505 -- Affordable Biologics for Consumers Act
S 1695 Biologics Price Competition and Innovation Act of 2007
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 2029 Physician Payments Sunshine Act of 2007
HR 6111 Tax Relief and Health Care Act (Medicare)
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization ActHR 3023 Drug and Medical Device Company Gift Disclosure Act
HR 3963 Children Health Insurance Reauthorization Act of 2007
S 2041 False Claims Act Correction Act of 2007
HR 3610 Food and Drug Import Safety Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 1145 Patent Reform Act of 2007
HR 1908 Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2008
RICCHETTI INCORPORATED amended a lobbying report for representation of NOVARTIS in Q12008 on April 17, 2008.
Original Filing: 300041136.xml
Lobbying Issues
H.R. 4703, S. 2467, HR 4991 -- Vaccine Shortage Preparedness Act of 2008
S 2467, HR 4703, HR 4991 -- A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act
HR 970 and S 1378 -- Dextromethorphan Distribution Act of 2007S 3678 -- Pandemic All Hazards Preparedness Act (Biodefense)
S 103 Combat Meth Act of 2005
HR 1908 -- and S 1710 -- Patent Reform Act of 2007
HR 3162 -- Children's Health and Medicare Protection Act of 2007
S 1505 -- Affordable Biologics for Consumers Act
S 1695 Biologics Price Competition and Innovation Act of 2007
Comparative effectiveness research
Drug importation
Direct to consumer advertising
Drug safety legislation
FDA funding
Issues related to the use of thimerisol in vaccines
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
FY 2009 Labor HHS Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
FY 2009 Supplemental Appropriations Bill
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 2029 Physician Payments Sunshine Act of 2007
HR 6111 Tax Relief and Health Care Act (Medicare)
Medicare Part B (prompt pay removal from ASP calculation) and Part D (non-interference)
Medicare Prescription Drugs and Modernization ActHR 3023 Drug and Medical Device Company Gift Disclosure Act
HR 3963 Children Health Insurance Reauthorization Act of 2007
S 2041 False Claims Act Correction Act of 2007
HR 3610 Food and Drug Import Safety Act of 2007
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S 1145 Patent Reform Act of 2007
HR 1908 Patent Reform Act of 2007
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...